Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.52 |
| ▸ | CDC25B | P30305 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747118 | 0.68 | S100A4 (1.00) | S100A4CDC25BIDO1MAOAMAOB | |
| SCHEMBL4066187 | 0.67 | TDP1 (0.42) | PLK4AURKACHEK2LCKCDK2 | |
| SCHEMBL5041817 | 0.65 | CTSL (0.53) | CDC25BMAOAMAOB | |
| SCHEMBL6607479 | 0.65 | MAOB (0.50) | S100A4CDC25BMAOAMAOB | |
| SCHEMBL6575939 | 0.65 | PTPRC (0.59) | S100A4CDC25BMAOAMAOB | |
| SCHEMBL11358184 | 0.62 | S100A4 (0.59) | S100A4CDC25BIDO1MAOAMAOB | |
| SCHEMBL28289103 | 0.62 | S100A4 (0.59) | S100A4CDC25BIDO1MAOAMAOB | |
| SCHEMBL6186385 | 0.62 | MAOA (0.52) | S100A4CDC25BIDO1MAOAMAOB | |
| SCHEMBL31511817 | 0.61 | S100A4 (0.54) | S100A4CDC25BIDO1MAOAMAOB | |
| SCHEMBL4536691 | 0.61 | CDC25B (0.46) | S100A4CDC25BIDO1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148437-A1 | Novel Ezrin Inhibitors and Methods of Making and Using | UNITED STATES GOVERNMENT | 2018-05-31 | — | — | US | disclosed |
| US-9522908-B2 | Ezrin inhibitors and methods of making and using | Gerogetown University (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140135325-A1 | NOVEL EZRIN INHIBITORS AND METHODS OF MAKING AND USING | GEORGETOWN UNIVERSITY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012064396-A9 | NOVEL EZRIN INHIBITORS AND METHODS OF MAKING AND USING | GEORGETOWN UNIVERSITY (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012064396-A2 | NOVEL EZRIN INHIBITORS AND METHODS OF MAKING AND USING | GEORGETOWN UNIVERSITY (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-0866692-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997021432-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA, S.A. (FR) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148437-A1 | Novel Ezrin Inhibitors and Methods of Making and Using | EZR, CDC42, ERMP1 | S100A4 1775/4885CDC25B 98/4885IDO1 4717/4885 |
| US-20140135325-A1 | NOVEL EZRIN INHIBITORS AND METHODS OF MAKING AND USING | EZR, NHERF1, ERMP1 | S100A4 1855/4885CDC25B 94/4885IDO1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.